{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=2&q=HPV-positive",
    "query": {
      "q": "HPV-positive",
      "condition": "Head and Neck Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Cancer&page=1&q=HPV-positive&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T02:07:20.668Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05061940",
      "title": "This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Melanoma",
        "HPV-Related Malignancy",
        "HPV-Related Carcinoma",
        "HPV-Related Cervical Carcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Lung Cancer, Nonsmall Cell",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Tumor Profiling",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Repertoire Immune Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-05-05",
      "completion_date": "2022-10-11",
      "has_results": false,
      "last_update_posted_date": "2022-12-06",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05061940"
    },
    {
      "nct_id": "NCT03978689",
      "title": "A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Related Carcinoma"
      ],
      "interventions": [
        {
          "name": "CUE-101",
          "type": "DRUG"
        },
        {
          "name": "KEYTRUDA®, Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cue Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2019-07-30",
      "completion_date": "2026-01-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Palo Alto, California • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03978689"
    },
    {
      "nct_id": "NCT04180215",
      "title": "A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HPV-Related Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "HB-201 intravenous administration.",
          "type": "DRUG"
        },
        {
          "name": "HB-202 intravenous administration alternating with HB-201 intravenous administration.",
          "type": "DRUG"
        },
        {
          "name": "HB-201 intravenous administration + standard of care regimen including pembrolizumab.",
          "type": "DRUG"
        },
        {
          "name": "HB-202 / HB-201 alternating intravenous administration + pembrolizumab.",
          "type": "DRUG"
        },
        {
          "name": "HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.",
          "type": "DRUG"
        },
        {
          "name": "HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hookipa Biotech GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2019-12-11",
      "completion_date": "2025-01-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04180215"
    },
    {
      "nct_id": "NCT03575234",
      "title": "Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
        "Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "IRX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-07-01",
      "completion_date": "2026-01-31",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03575234"
    },
    {
      "nct_id": "NCT02113878",
      "title": "Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell of Head and Neck",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Hypopharyngeal Cancer",
        "Early Invasive Cervical Squamous Cell Carcinoma",
        "Carcinoma of Larynx",
        "Cancer of Nasopharynx"
      ],
      "interventions": [
        {
          "name": "BKM120",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-modulated radiotherapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2014-09-29",
      "completion_date": "2022-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113878"
    },
    {
      "nct_id": "NCT01898494",
      "title": "Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Papilloma Virus Infection",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx"
      ],
      "interventions": [
        {
          "name": "Transoral surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "intensity-modulated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 519,
      "start_date": "2014-01-22",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01898494"
    },
    {
      "nct_id": "NCT06868433",
      "title": "TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hypopharyngeal Squamous Cell Carcinoma",
        "Metastatic Laryngeal Squamous Cell Carcinoma",
        "Metastatic Nasopharyngeal Squamous Cell Carcinoma",
        "Metastatic Oral Cavity Squamous Cell Carcinoma",
        "Metastatic Oropharyngeal Squamous Cell Carcinoma",
        "Metastatic Sinonasal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Nasopharyngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Sinonasal Squamous Cell Carcinoma",
        "Squamous Cell Carcinoma of Unknown Primary",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Hypopharyngeal Carcinoma AJCC v8",
        "Stage IV Laryngeal Cancer AJCC v8",
        "Stage IV Lip and Oral Cavity Cancer AJCC v8",
        "Stage IV Nasopharyngeal Carcinoma AJCC v8",
        "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IV Sinonasal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Autologous Tumor Membrane Vesicles Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-05-08",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06868433"
    },
    {
      "nct_id": "NCT03224000",
      "title": "Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasms of Lip Oral Cavity and Pharynx",
        "Oropharyngeal Cancer"
      ],
      "interventions": [
        {
          "name": "Modified Barium Swallow (MBS)",
          "type": "PROCEDURE"
        },
        {
          "name": "Swallowing Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Symptom Questionnaire",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Video-Strobe Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning",
          "type": "PROCEDURE"
        },
        {
          "name": "Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning",
          "type": "PROCEDURE"
        },
        {
          "name": "Intensity Modulated Radiotherapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BEHAVIORAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2018-01-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03224000"
    },
    {
      "nct_id": "NCT04666428",
      "title": "Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-01-24",
      "completion_date": "2023-01-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666428"
    },
    {
      "nct_id": "NCT03601507",
      "title": "Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CDKN2A-p16 Positive",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7",
        "Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacodynamic Study",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9,
      "start_date": "2019-03-11",
      "completion_date": "2022-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-09-02T02:07:20.668Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03601507"
    }
  ]
}